NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say

Core Insights - NovoCure reported revenue of $158.81 million for the quarter ended June 2025, reflecting a year-over-year increase of 5.6% [1] - The company's EPS was -$0.36, a slight decline from -$0.31 in the same quarter last year [1] - Revenue exceeded the Zacks Consensus Estimate of $153.83 million by 3.24%, while EPS also surpassed expectations by 7.69% [1] Financial Performance - The reported revenue of $158.81 million indicates a positive trend compared to the previous year [1] - EPS of -$0.36 shows a deterioration in earnings performance compared to the prior year's -$0.31 [1] - The company achieved a revenue surprise of +3.24% and an EPS surprise of +7.69% against analyst estimates [1] Geographic Revenue Breakdown - Revenue from Greater China was $4.59 million, exceeding the average estimate of $3.7 million [4] - Revenue from Japan reached $9.48 million, surpassing the average estimate of $8.54 million [4] - Revenue from the United States was $94.26 million, slightly above the average estimate of $93.78 million [4] Stock Performance - NovoCure's shares have declined by 4.7% over the past month, contrasting with a 5.7% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]